Connect with us

Health

Horace Hale Harvey III, a Pioneer in Providing Abortions, Dies at 93

Published

on

Horace Hale Harvey III, a Pioneer in Providing Abortions, Dies at 93

On July 1, 1970, one of the first independent abortion clinics in the country opened on the Upper East Side of Manhattan. New York State had just reformed its laws, allowing a woman to terminate her pregnancy in the first trimester — or at any point, if her life was at risk. All of a sudden, the state had the most liberal abortion laws in the country.

Women’s Services, as the clinic was first known, was overseen by an unusual team: Horace Hale Harvey III, a medical doctor with a Ph.D. in philosophy who had been performing illegal abortions in New Orleans; Barbara Pyle, a 23-year-old doctoral student in philosophy, who had been researching sex education and abortion practices in Europe; and an organization known as Clergy Consultation Service on Abortion, a group of rabbis and Protestant ministers who believed that women deserved access to safe and affordable abortions, and who had created a referral service to find and vet those who would provide them.

What distinguished Women’s Services — a nonprofit that first operated out of a series of offices on East 73rd Street and charged on a sliding scale, starting at $200 — was its counselors. They were not medical professionals, but regular women, many of whom had had abortions themselves. Their role was to shepherd patients through the abortion process, using a model of a pelvis to explain the procedure in detail, accompanying the women into the procedure room and sitting with them afterward. They also reported on the doctor’s performance. It was a model that other clinics would adopt in the months and years to come.

The clinic’s humane approach was in stark contrast to the attitude of many hospital personnel at the time, Jane Brody of The New York Times wrote in 1970. “Don’t make it too easy for the patient,” one administrator put it, summing up the hospital’s philosophy. “If it’s too easy, she’ll be back here in three months for another abortion.”

Women’s Services had some other unique features as well. The waiting areas were cheerfully decorated, with piped-in music, and the operating tables had stirrups cushioned with brightly colored pot holders, a flourish Dr. Harvey, who died on Feb. 14, had brought with him from his days working out of hotel rooms in New Orleans.

Advertisement

Unlike many illegal abortion providers in those pre-Roe v. Wade days, who made the process as bare-bones and speedy as possible in anticipation of a police raid, Dr. Harvey had not only softened the atmosphere of his New Orleans procedure room to make it less terrifying; he had also offered the women cookies and Coca-Cola afterward, to help them recuperate.

“Harvey’s conviction was that even a healthy patient would feel sick, in the face of a cold, sterile hospital environment,” Arlene Carmen and the Rev. Howard Moody, the leaders of Clergy Consultation Service, wrote in their 1973 book about the group, “Abortion Counseling and Social Change From Illegal Act to Medical Practice.” “Since abortion was not a sickness, the atmosphere associated with hospitals needed to be avoided.”

Dr. Harvey was 93 when he died at a hospital in the town of Dorchester, in England, after a fall, his daughter Kate Harvey, said. He had lived in England for many years.

Women’s Services opened with $15,000 in funding from Dr. Harvey. Ms. Pyle, who was the administrator, described in an interview the chaotic early days, as clients poured in from all over the country. The clinic operated from 8 a.m. to midnight, with personnel working two shifts. Ms. Pyle slept on a couch in the building. On average, she said, the clinic performed about 72 abortions a day.

Newspapers wrote glowing reports, singling out Dr. Harvey as an innovator. But after less than a year, Ms. Carmen and Mr. Moody, of the Clergy Consultation Service, discovered to their horror that Dr. Harvey had been operating without a medical license. He had surrendered it in 1969, after the Louisiana authorities learned that he was performing illegal abortions. He had to go, and quickly, before he jeopardized Women’s Services’ legal status.

Advertisement

Dr. Harvey had become an abortion provider to combat what he felt was an epidemic of unsafe abortions at a time when unmarried women were denied access to contraceptives, and when comprehensive sex education was discouraged. Low-income women suffered disproportionally.

As a teenager, raised as a conservative Christian, Dr. Harvey had gone through a period of soul-searching, concluding that he was an atheist. During the Vietnam War, he registered as a conscientious objector; instead of fighting, he worked as a health counselor at a Y.M.C.A. Later, in New Orleans, he set up an independent sex-education program, giving lectures, answering questions by telephone and handing out brochures on college campuses.

To Dr. Harvey, the importance of abortion was the idea of preventing “the loss of potential for women,” Ms. Harvey, his daughter, said. “It was a matter of principle to him.”

Horace Hale Harvey III was born on Dec. 7, 1931, in New Orleans into a once-prominent family that had developed what is known as the Harvey Canal, which became part of the Intracoastal Waterway in 1924. His father, Horace Hale Harvey Jr., was a gambler, and the family was poor; they moved around a lot as he tried various professions, including setting up a loan company. His mother, Florence (Krueger) Harvey, was a secretary.

Horace studied philosophy at Louisiana State University, earning a bachelor’s degree in 1955, and a medical degree there in 1966. In 1969, he received a master’s degree in public health and a Ph.D. in philosophy, both from Tulane University, in New Orleans.

Advertisement

Dr. Harvey moved to England after leaving the New York abortion clinic — a choice he made, his daughter said, because he approved of Britain’s National Health Service. He settled on the Isle of Wight, another considered choice: According to his research, it had the highest average temperature and received more hours of sunlight than anywhere else in England.

Dr. Harvey worked briefly in public health in his new country, advising on cervical cancer screening procedures, but spent most of his time researching aging — to prepare for his own old age — reading philosophy and attending to his duties as a landlord.

He had bought Puckaster Close, a rambling Victorian house, turning it into apartments that he renovated in a style as “quirky and characterful” as Dr. Harvey himself, his son, Russell, said.

In addition to his daughter and son, Dr. Harvey is survived by three grandchildren. His marriage to Helen Cox, a school headmistress, ended in divorce.

Advertisement

Health

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

Published

on

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

NEWYou can now listen to Fox News articles!

A new study suggests that middle-aged men may be more vulnerable to faster biological aging, potentially linked to exposure to “forever chemicals.”

The research, published in the journal Frontiers in Aging, examined how perfluoroalkyl and polyfluoroalkyl substances, more commonly known as PFAS, could impact aging at the cellular level.

PFAS are synthetic chemicals commonly used in nonstick cookware, food packaging, water-resistant fabrics and other consumer products, the study noted. 

Their chemical structure makes them highly resistant to breaking down, allowing them to accumulate in water, soil and the human body.

Advertisement

Chinese researchers analyzed blood samples from 326 adults enrolled in the U.S. National Health and Nutrition Examination Survey between 1999 and 2000.

A new study suggests that middle-aged men could face accelerated biological aging at the cellular level due to exposure to PFAS. (iStock)

The researchers measured levels of 11 PFAS compounds in participants’ blood and used DNA-based “epigenetic clocks” — tools that analyze chemical changes to DNA to estimate biological age — to determine how quickly their bodies were aging at the cellular level, the study stated.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Two compounds, perfluorononanoic acid (PFNA) and perfluorooctanesulfonamide (PFOSA), were detected in 95% of participants.

Advertisement

Higher concentrations of those chemicals were associated with faster biological aging in men of certain age groups, but not in women.

“People should not panic.”

The compounds most strongly linked to accelerated aging were not the PFAS chemicals that typically receive the most public attention, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“The associations were strongest in adults aged 50 to 64, particularly in men,” Dr. Xiangwei Li, professor at Shanghai Jiao Tong University School of Medicine and the study’s corresponding author, told Fox News Digital. 

Advertisement

“While this does not establish that PFAS cause aging, it suggests that these widely present ‘forever chemicals’ may be linked to molecular changes related to long-term health and aging.”

The study found that two of the compounds were detected in 95% of participants, and higher levels were linked to faster biological aging in men ages 50–64. (iStock)

Midlife may represent a more sensitive biological period, when the body becomes more vulnerable to age-related stressors, according to the researchers.

Lifestyle factors, such as smoking, may influence biological aging markers, potentially increasing vulnerability to environmental pollutants.

Advertisement

While Li said “people should not panic,” she does recommend looking for reasonable ways to reduce exposure. 

That might mean checking local drinking water reports, using certified water filters designed to reduce PFAS, and limiting the use of stain- or grease-resistant products when alternatives are available.

CLICK HERE FOR MORE LIFESTYLE STORIES

Meaningful reductions in PFAS exposure will likely depend on broader regulatory action and environmental cleanup efforts, Li added.

The researchers noted that midlife could be a particularly sensitive stage, when the body is more susceptible to stressors associated with aging. (iStock)

Advertisement

Study limitations

The researchers outlined several important limitations of the research, including that the findings show an association, but do not prove that PFAS directly causes accelerated aging.

“The study is cross-sectional, meaning exposure and aging markers were measured at the same time, so we cannot determine causality,” Li told Fox News Digital.

The study was also relatively small, limited to 326 adults age 50 or older, which means the findings may not apply to younger people or broader populations.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Researchers measured PFAS levels using data collected between 1999 and 2000, and today’s exposure patterns may differ.

Advertisement

Li added that while PFAS is known to persist in the environment and the body, these results should be validated through larger, more recent studies that follow participants over time.

Related Article

Nightly bathroom habit was missed sign of common men's cancer: 'I didn't know'
Continue Reading

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Alzheimer’s prevention breakthrough found in decades-old seizure drug

Published

on

Alzheimer’s prevention breakthrough found in decades-old seizure drug

NEWYou can now listen to Fox News articles!

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests.

The anti-seizure medication, levetiracetam, was first approved by the FDA in November 1999 under the brand name Keppra as a therapy for partial-onset seizures in adults. The approval has since expanded to include children and other types of seizures.

Northwestern University researchers recently found that levetiracetam prevented the formation of toxic amyloid beta peptides, which are small protein fragments in the brain that are commonly seen in Alzheimer’s patients.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons, according to the study findings, which were published in Science Translational Medicine.

Advertisement

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease.

The medication was found to prevent the formation of amyloid-beta 42 in both animal models and cultured human neurons. (iStock)

“While many of the Alzheimer’s drugs currently on the market, such as lecanemab and donanemab, are approved to clear existing amyloid plaques, we’ve identified this mechanism that prevents the production of the amyloid‑beta 42 peptides and amyloid plaques,” said corresponding author Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine, in a press release. 

“Our new results uncovered new biology while also opening doors for new drug targets.”

HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS

Advertisement

The brain is better able to avoid the pathway that produces toxic amyloid‑beta 42 proteins in younger years, but the aging process gradually weakens that ability, Savas noted. 

“This is not a statement of disease; this is just a part of aging. But in brains developing Alzheimer’s, too many neurons go astray, and that’s when you get amyloid-beta 42 production,” he said. 

The effect was also seen in post-mortem human brain tissue obtained from individuals with Down syndrome, who are at high risk for Alzheimer’s disease. (iStock)

That then leads to tau (“tangles”) — abnormal clumps of protein inside brain neurons — which can kill brain cells, trigger neuroinflammation and lead to dementia.

In order for levetiracetam to function as an Alzheimer’s blocker, high-risk patients would have to start taking it “very, very early,” Savas said — up to 20 years before elevated amyloid-beta 42 levels would be detected.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death,” the researcher noted.

The researchers also did a deep dive into previous human clinical data to determine whether Alzheimer’s patients who were taking the anti-seizure drug had slower cognitive decline. They reported that the patients in that category had a “significant delay” in the span from cognitive decline to death compared to those not taking the drug.

“This analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” the researcher said. (iStock)

“Although the magnitude of change was small (on the scale of a few years), this analysis supports the positive effect of levetiracetam to slow the progression of Alzheimer’s pathology,” Savas said.

Advertisement

Looking ahead, the research team aims to find people who have genetic forms of Alzheimer’s to participate in testing, Savas said.

Limitations and caveats

The study had several limitations, including that it relied on animal models and cultured cells, with no human trials conducted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Because the study was observational in nature, it can’t prove that the medication caused the prevention of the toxic brain proteins, the researchers acknowledged.

Savas noted that levetiracetam “is not perfect,” cautioning that it breaks down in the body very quickly.

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The team is currently working to create a “better version” that would last longer in the body and “better target the mechanism that prevents the production of the plaques.”

“You couldn’t take this when you already have dementia, because the brain has already undergone a number of irreversible changes and a lot of cell death.”

The medication’s common documented side effects include drowsiness, weakness, dizziness, irritability, headache, loss of appetite and nasal congestion.

It has also been linked to potential mood and behavior changes, including anxiety, depression, agitation and aggression, according to the prescribing information. In rare cases, it could lead to severe allergic reactions, skin reactions, blood disorders and suicidal ideation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Funding for the study was provided by the National Institutes of Health and the Cure Alzheimer’s Fund.

Fox News Digital reached out to the drug manufacturer and the researchers for comment.

Related Article

Alzheimer’s decline could slow dramatically with one simple daily habit, study finds
Continue Reading
Advertisement

Trending